Baird lowered the firm’s price target on iRhythm (IRTC) to $79 from $100 and keeps an Outperform rating on the shares. The firm said its tough to again stick their neck out for a name that has had several product timeline delays and they are cautiously optimistic that the voluntary-delay now accounts for prior “unknowns” associated with the ongoing Warning Letter/483-observation remediation process.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRTC:
- iRhythm Technologies Faces Potential Stockholder Dilution and Market Pressure from 2029 Notes Conversion
- iRhythm price target lowered to $125 from $137 at Canaccord
- iRhythm Technologies Reports Strong Revenue Growth in Q3 2024
- iRhythm gets FDA 510(k) clearance for design modifications to Zio AT device
- iRhythm reports Q3 EPS($1.26) , consensus (57c)